Physician profile
Joshua Evans
NPI 1861579450
$33,719.85
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,384 · 2020: $12K · 2021: $7,388 · 2022: $4,907 · 2023: $60.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,945.16 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,272.67 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $434.97 | 2019-2023 | Entyvio |
| Qol Medical, LLC | $312.58 | 2019-2022 | |
| Celgene Corporation | $279.85 | 2021-2022 | |
| Janssen Biotech, INC. | $184.34 | 2021-2023 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $81.25 | 2019-2022 | |
| Genzyme Corporation | $46.21 | 2022 | |
| Intercept Pharmaceuticals, INC. | $45.41 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $22.98 | 2022 | |
| Organon LLC | $21.72 | 2022 | |
| Amgen INC. | $17.24 | 2022 | |
| Welch Allyn | $16.90 | 2021 | |
| Merck Sharp & Dohme LLC | $14.27 | 2022 | |
| Baxter Healthcare | $12.67 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.